Good morning :)
Place Order
Add to Watchlist

IPCA Laboratories Ltd

IPCALAB

IPCA Laboratories Ltd

IPCALAB
Health CarePharmaceuticals
MidcapWith a market cap of ₹38,178 cr, stock is ranked 215
Moderate RiskStock is 2.03x as volatile as Nifty
1,504.853.50% (-54.65)
1,504.853.50% (-54.65)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹38,178 cr, stock is ranked 215
Moderate RiskStock is 2.03x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹38,178 cr, stock is ranked 215
Moderate RiskStock is 2.03x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
66.194.940.27%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.796.290.52%

Forecast & Ratings

Detailed Forecast 
60%
Analysts have suggested that investors can buy this stock

from 15 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.74%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.73% to 2.09%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 4.24%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2,889.333,168.943,299.563,803.374,686.035,482.835,896.366,369.947,897.828,381.47
Raw Materialssubtract1,032.551,115.711,101.281,355.151,820.251,923.092,144.502,205.842,706.396,982.43
Power & Fuel Costsubtract141.67151.00161.92176.50201.22207.10242.12283.74333.97
Employee Costsubtract625.58695.98735.88787.40921.231,013.571,177.391,287.641,708.43
Selling & Administrative Expensessubtract532.58596.75598.72524.85545.44575.16641.87704.69853.53
Operating & Other expensessubtract242.49147.58205.93208.35228.73153.49311.14832.99954.84
Depreciation/Amortizationsubtract163.26172.95177.73182.42210.50209.17232.42261.56357.24386.86
Interest & Other Itemssubtract34.5626.9127.5722.2419.7712.2711.2048.19140.75130.94
Taxes & Other Itemssubtract23.5067.5251.11101.63132.57248.97251.64273.97295.32304.47
EPS3.697.7112.6535.2347.9959.9934.8518.5821.5722.73
DPS0.000.501.003.005.004.004.004.004.002.00
Payout ratio0.000.060.080.090.100.070.110.220.190.09

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2019

Annual report

PDF

Investor Presentation

Nov 12PDF
FY 2023

Annual Report Unavailable

 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
IPCA Laboratories Ltd69.754.940.27%
Sun Pharmaceutical Industries Ltd44.576.360.76%
Cipla Ltd29.504.540.86%
Torrent Pharmaceuticals Ltd63.6815.380.90%

Price Comparison

Compare IPCALAB with any stock or ETF
Compare IPCALAB with any stock or ETF
IPCALAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.30%28.55%5.68%10.83%8.64%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep10.05%9.86%10.27%10.51%10.85%10.83%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding IPCA Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan

Growth
6.5692%3.35%0.52%5/79 (+3)
Kotak Emerging Equity Fund - Growth - Direct Plan

Growth
3.8501%3.01%0.64%45/75 (+3)
DSP Midcap Fund - Growth - Direct Plan

Growth
1.8417%3.60%0.23%1/64 (+1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have IPCA Laboratories Ltd

Events

Dividend Trend

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.66 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 6, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Aug 6, 2024

Cash Dividend

Ex DateEx DateNov 22, 2023

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Nov 22, 2023

Cash Dividend

Ex DateEx DateNov 22, 2022

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

₹4.00

Ex DateEx Date

Nov 22, 2022

Cash Dividend

Ex DateEx DateNov 22, 2021

Interim
Interim | Div/Share: ₹8.00

Dividend/Share

₹8.00

Ex DateEx Date

Nov 22, 2021

Cash Dividend

Ex DateEx DateNov 13, 2020

Interim
Interim | Div/Share: ₹8.00

Dividend/Share

₹8.00

Ex DateEx Date

Nov 13, 2020

News & Opinions
Corporate
Ipca Laboratories schedules board meeting

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Ipca Laboratories fixes record date for interim dividend

Ipca Laboratories has fixed 22 November 2024 as record date for payment of interim dividend that may be declared at the meeting of the Board of Directors of the Company scheduled to be held on 14 November 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Live Market Update
Sensex, Nifty pare gains; IT shares advance

The domestic equity benchmarks pared all gains and traded with minor losses in morning trade. The Nifty traded below the 25,800 level. IT shares advanced after declining for the past trading sessions. At 10:30 ST, the barometer index, the S&P BSE Sensex, was down 3.32 points or 0.01% to 84,298.60. The Nifty 50 index fell 13.15 points or 0.05% to 25,794.15. In the broader market, the S&P BSE Mid-Cap index shed 0.12% and the S&P BSE Small-Cap index added 0.27%. The market breadth was strong. On the BSE, 2,265 shares rose and 1,324 shares fell. A total of 166 shares were unchanged. Due to the observance of Mahatma Gandhi Jayanti on Wednesday, 2 October 2024, the domestic market will be closed. Economy: India's fiscal deficit remained under control during April-August, reaching 27% of the full-year target. This containment was attributed to muted spending in the early months of the fiscal year. The government's spending has been lower due to general elections. In comparison, the deficit stood at a higher 36% during the same period in FY24. Buzzing Index: The Nifty IT index added 0.91% to 42,329.55. The index declined 0.87% in the past trading sessions. Tech Mahindra (up 3.16%), Infosys (up 1.53%), Wipro (up 1.1%), Mphasis (up 1.1%) and Coforge (up 0.91%), Persistent Systems (up 0.54%), HCL Technologies (up 0.08%), LTIMindtree (up 0.06%), L&T Technology Services (up 0.01%) edged higher. Stocks in Spotlight: India Glycols advanced 7.86% after the company has increased its grain-based distillery capacity by 100 KLPD at Kashipur, Uttarakhand and added 180 KLPD to its existing bio-fuel ethanol plant at the same location. Additionally, it has expected its facilities for new value-added chemicals products by 2500 MTPA in Kashipur, Uttarakhand. IPCA Laboratories fell 1.11% after the company's subsidiary, Bayshore will sell nine ANDAs to US-based Unichem for $2.65million, along with its generic business for $10 million.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Ipca Laboratories approves consolidation of USA generic formulations biz

The Board of Ipca Laboratories at its meeting held on 30 September 2024 has approved entering into the following agreements by Bayshore Pharmaceuticals LLC, USA (Bayshore) (wholly-owned step down subsidiary) with Unichem Laboratories (Unichem India) (subsidiary company) and Unichem Pharmaceuticals (USA) Inc (Unichem USA) (wholly owned subsidiary of Unichem India), so as to integrate and consolidate all the Ipca Group's USA generic formulations business under one entity: a) Sale of all rights, title and interest in the product approvals and all goodwill associated with nine (9) ANDAs owned by Bayshore for US Dollar Two Million Six Hundred Fifty Thousand ($2,650,000) through asset sale agreement subject to necessary consents/ approvals to Unichem India; and b) Sale of all generic formulations marketing / distribution business of Bayshore in the US market as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business through business sale agreement for US Dollar Ten Millions ($10,000,000) to Unichem USA.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Ipca Laboratories schedules board meeting

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 30 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd up for third consecutive session

Ipca Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1457, up 3.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Ipca Laboratories Ltd has gained around 10.43% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 10.05 lakh shares today, compared to the daily average of 5.44 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1461.2, up 3.01% on the day. Ipca Laboratories Ltd is up 62.35% in last one year as compared to a 28.41% jump in NIFTY and a 52.01% jump in the Nifty Pharma index.The PE of the stock is 58.06 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd soars 2.3%, rises for third straight session

Ipca Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 1416.1, up 2.3% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24728.5. The Sensex is at 80764.15, down 0.05%. Ipca Laboratories Ltd has added around 16.67% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 9.29% in last one month and is currently quoting at 22374.25, up 0.83% on the day. The volume in the stock stood at 6.38 lakh shares today, compared to the daily average of 5.41 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1418, up 2.58% on the day. Ipca Laboratories Ltd is up 60.02% in last one year as compared to a 27.49% gain in NIFTY and a 47.43% gain in the Nifty Pharma index.The PE of the stock is 57.01 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Ipca Laboratories consolidated net profit rises 18.07% in the June 2024 quarter

Net profit of Ipca Laboratories rose 18.07% to Rs 192.24 crore in the quarter ended June 2024 as against Rs 162.82 crore during the previous quarter ended June 2023. Sales rose 32.01% to Rs 2092.63 crore in the quarter ended June 2024 as against Rs 1585.21 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales2092.631585.21 32 OPM %18.7719.41 - PBDT389.28321.09 21 PBT290.39251.82 15 NP192.24162.82 18 Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd gains for fifth session

Ipca Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1378.5, up 0.94% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 24427.1. The Sensex is at 79938.07, up 0.29%. Ipca Laboratories Ltd has risen around 12.3% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 6.42% in last one month and is currently quoting at 22209.55, down 0.12% on the day. The volume in the stock stood at 2.55 lakh shares today, compared to the daily average of 4.36 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1374.65, up 0.59% on the day. Ipca Laboratories Ltd is up 55.86% in last one year as compared to a 25.69% spurt in NIFTY and a 44.93% spurt in the Nifty Pharma index.The PE of the stock is 57.68 based on TTM earnings ending March 24.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd soars 2.1%

Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1368.65, up 2.1% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 24269.55. The Sensex is at 79387.27, down 0.1%. Ipca Laboratories Ltd has risen around 12.12% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 7.67% in last one month and is currently quoting at 22036.95, up 0.88% on the day. The volume in the stock stood at 4.13 lakh shares today, compared to the daily average of 4.08 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1370, up 1.84% on the day. Ipca Laboratories Ltd is up 50.09% in last one year as compared to a 23.62% spurt in NIFTY and a 41.62% spurt in the Nifty Pharma index.The PE of the stock is 56.72 based on TTM earnings ending March 24.Powered by Capital Market - Live

3 months agoCapital Market - Live